Nanolattix’s TF-Targeting Radiopharmaceutical RDC Selected for AACR, Accelerating Theranostic System Deployment

At the upcoming 2026 Annual Meeting of the American Association for Cancer Research (AACR), "Radiopharmaceutical Platforms for Theranostic Precision Oncology" has emerged as a key focus area for cutting-edge technological exploration. Based on disclosed research content, development efforts surrounding radioligands, RDC platforms, and novel radionuclide combinations continue to intensify, spanning multiple dimensions such as novel target discovery, vector optimization, dosimetry, and imaging evaluation. This reflects that radiopharmaceuticals are transitioning from isolated product exploration towards platform-based and systematic development.

Against this backdrop, research findings related to RT01, a theranostic radiopharmaceutical (RDC) independently developed by Nanolattix, have been selected for the aforementioned session and will be presented during the conference.

RT01 is a theranostic RDC targeting tissue factor (TF), comprising a humanized antibody conjugated with the diagnostic radionuclide zirconium-89 (89Zr) and the therapeutic radionuclides lutetium-177 (177Lu) and actinium-225 (Ac-225). In preclinical studies, RT01 demonstrated rapid and specific tumor accumulation in tumor models, exhibited prolonged target retention in lesions, along with swift clearance from non-target tissues, showcasing favorable in vivo distribution characteristics.

Further studies have shown that RT01 exhibits significant antitumor activity and a favorable safety profile under single-dose administration, supporting its further clinical development in TF-positive tumors. Currently, RT01 has entered investigator-initiated trial (IIT) stage, with the first subject having been dosed. Preliminary imaging results indicate favorable tumor accumulation and target-to-background contrast characteristics. Relevant research is ongoing, with plans to further expand enrollment and evaluation in patients with various types of solid tumors.

The significance of RT01 lies not only in the advancement of a radiopharmaceutical product but also in its pivotal role within Nanolattix's "ADC + RDC theranostic" system. Within this system, RDCs and ADCs are not developed independently but are synergistically designed based on the "same target, same antibody/ligand" principle: the RDC tumor-targeted imaging component provides "visualization clarity," offering visual data on in vivo distribution and target expression; the therapeutic RDC and ADC are responsible for "precision attack," achieving efficient tumor cell killing. This creates a continuous closed loop from identification to intervention. Currently, related ADC pipelines are also advancing in parallel, with T320 having entered Phase I clinical trials, and the HER2/TF bispecific ADC B836 being selected for a relevant session at this year's AACR.

Building on this foundation, the value of RDC is further amplified. Different from the traditional approach of "administer the drug first, then determine its efficacy," RDC, through molecular imaging, directly visualizes the drug's in vivo distribution, accumulation, and target expression status. This provides a basis for decisions on "whether to treat and how to treat," shifting therapeutic decision-making from empirical judgment to visualization-supported evidence.

This capability also transforms R&D logic and efficiency. In early clinical development, utilizing imaging techniques with diagnostic radionuclides allows for direct observation of a candidate molecule's in vivo behavior, determining whether it truly reaches the tumor and possesses sufficient target accumulation capability. This enables earlier selection of effective molecules and optimization of dosing and combination strategies. Consequently, within Nanolattix's system, RDC serves not only as a therapeutic tool but also functions as a "R&D navigator," connecting molecular design, in vivo validation, and clinical decision-making.

As RT01 progresses into the clinical stage, Nanolattix's theranostic system built around RDC is moving from single-point technology validation towards practical application. Concurrently, Nanolattix has established a pipeline matrix in the RDC field encompassing monoclonal antibodies, bispecific antibodies, and nanobodies. Among these, the active advancement of four bispecific antibody RDC pipelines under the RB series further strengthens the comprehensive layout of this system, providing more definitive and layered solutions for precision oncology.